CDLX

Cardlytics, Inc. (CDLX) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 4.8 (Moderate)

Revenue expansion is constrained by the absence of disclosed five-year CAGR data and negative TTM ROIC, which limits evidence of durable compounding versus peers.

R&D intensity at 16.0% of revenue supports product iteration, but peers with stronger monetization and positive returns likely convert investment into growth more efficiently.

Low capex at 2.5% of revenue suggests an asset-light model, yet the lack of proven multi-year revenue acceleration caps confidence in scalable expansion.

Negative EV-to-EBITDA and weak cash generation indicate current economics are not yet translating into repeatable growth, unlike better-capitalized peers with clearer reinvestment flywheels.

Market Tailwinds

Score:

The company appears to operate in a software-adjacent, data-driven market, but no filing evidence here shows a structural demand tailwind stronger than direct peers.

Asset-light economics can support faster adoption than capital-intensive peers, yet the negative ROIC suggests market demand has not produced durable monetization.

Compared with peers that show sustained revenue CAGR and positive operating leverage, CDLX lacks disclosed proof of a stronger long-term demand runway.

The available metrics imply a viable market, but not one with demonstrated multi-year compounding visibility or superior expansion momentum versus peers.

Scalability Expansion

Score:

Low capex requirements improve scalability, but the high cash conversion cycle of 138.6 days weakens working-capital efficiency versus more scalable peers.

R&D spending can be scaled without heavy fixed-asset investment, yet negative ROIC shows incremental spend is not clearly compounding revenue efficiently.

Negative interest coverage and negative EBITDA indicate expansion is not yet self-funding, which limits reinvestment capacity relative to profitable peers.

The business model may scale operationally, but current financial evidence does not show the strong operating leverage needed for top-tier long-term expansion.

Constraints Limitations

Score:

Negative TTM ROIC of -45.9% is the clearest structural constraint, because it signals capital is not being converted into durable revenue growth.

A 138.6-day cash conversion cycle ties up working capital, which reduces flexibility to reinvest faster than peers with tighter cash cycles.

Negative interest coverage and EBITDA imply limited internal funding capacity, constraining expansion relative to peers with self-financing growth engines.

The absence of disclosed five-year growth metrics leaves long-term compounding unproven, and peers with verified CAGR profiles have a clearer scalability advantage.

Overall Score

Score:

CDLX shows an asset-light structure and ongoing R&D investment, but negative returns, weak cash generation, and limited proof of durable revenue compounding keep long-term growth capacity below stronger peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Cardlytics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →